Yahoo Finance

Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development

SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced its primary ...
Yahoo Finance

Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327

Results demonstrate efficacy on bacterial growth in participants injected with RECCE ® 327 (R327) at the highest tested dose of 4,000mg No serious adverse events and clinically significant changes ...
The Australian

Recce secures $30m debt facility to support Phase III trials

Special Report: Developer of a new class of synthetic anti-infectives, Recce Pharmaceuticals is boosting its balance sheet securing a debt facility of up to ~$30 million to support Phase III ...
The Australian

Recce secures Chinese patent as it targets superbugs with new anti-infectives

Special Report: Recce Pharmaceuticals has secured patent acceptance in China for its synthetic anti-infectives RECCE® 327 (R327) and RECCE® 529 (R529) as it targets the growing global health problem ...
manilatimes

Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated ...

Phase II trial assessed the efficacy and safety of RECCE ® 327 topical gel in patients with acute bacterial skin and skin structure infections (ABSSSI), including those with diabetic foot infections ...